Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 1.00 0.95 1.05 1.00 1.00 1.00 963,333 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.4 -1.4 -0.2 - 11

Feedback Share Discussion Threads

Showing 11501 to 11521 of 11525 messages
Chat Pages: 461  460  459  458  457  456  455  454  453  452  451  450  Older
DateSubjectAuthorDiscuss
24/6/2021
18:45
Https://www.youtube.com/watch?v=MMzd40i8TfA
lr2
24/6/2021
14:29
I have done a little more research since last week, asking all my radiologist and oncologist contacts about the usefulness of a device like Bleepa, describing it though without naming it. The summary response is "we already......" or "that wouldn't work for us because...." or "out IT department have their own system designed for our specific clinical needs at this hospital". There is almost no interest in changing because there is so much else coming at them each day. Has anyone else here done their own research - many take pride in researching the businesses in the shares they own on this thread, but it would be useful for all and quite a simple matter for everybody to do a bit of enquiring themselves directly to medical contacts, and share the results here for everyone's benefit? There is no downside to the truth, whatever we find that to be
ydderf
24/6/2021
11:33
I think he needs a different approach. ie. "installing and using Bleepa is highly inadvisable which may leave you open to civil court action and fines".
digger2779
24/6/2021
11:09
Not sure about the last sentence but otherwise sounds quite hopeful. Bleepa is a simple idea that combines medical image sharing with clinical communications through a mobile app. It’s similar in its ease of use to WhatsApp but it’s totally secure. The app has received regulatory certification, giving clinicians the confidence and trust that they need. Although it’s simple, it has taken decades of imaging expertise, combined with digital know-how. Moreover, and importantly, vision, to make it happen. For India, Bleepa can support any hospitals and healthcare institutions. And it can do this without location being a constraint. Currently, access to centres of excellence in the four major cities is not possible for all, with both capacity and funding limiting access to top-tier treatment. New technologies, such as Bleepa, can provide the vital digital link between these centres of excellence and regional, hub and spoke models or even mobile care units. This enables millions more patients to receive the high standards of care targeted in the National Digital Health Mission. And this is just one technology – with so many on offer to review, and with the nation’s willingness to enable change, just think of the new world-class healthcare system we can create in India. Https://fbkmed.com/modernising-indias-healthcare-system/
ged5
23/6/2021
11:21
Well that's good! The end of the article was missing yesterday. Now just look here you purchasers for NHS Trusts. There's a bloody good App available. Now help us suffering shareholders and sign the contracts. You know it makes sense! Reduction in Administrative Support 100% of all inpatient respiratory referrals can be managed without admin support freeing time to focus on other tasks. Response Times Benchmarking for respiratory inpatient referrals showed that the existing process took on average 2.1 days before the receiving team got to review the referrals. With the introduction of Bleepa and the removal of the manual administrative steps, referrals are actioned within 0.4 days. This represents a saving of 1.7 days per referral. Releasing Time to Care A benchmarking audit shows that the process of responding to referrers can take on average 7.5 minutes per referral. The introduction of Bleepa reduces this response time to less than one minute by enabling a receiving doctor to respond using the chat in Bleepa. This results in a clinical time saving of approximately 6.5 minutes per referral. This equates to 5.6 weeks of a full-time clinician’s time released per annum based on current usage and a prediction of 36.3 weeks of clinical time per annum released if the project is expanded to all other medical teams. Figures based on benefits realisation analysis undertaken by Royal Oldham Hospital. Https://bleepa.com/referrals-process-improvements-and-time-savings
ged5
21/6/2021
23:56
It is a little mystery why that release suddenly disappeared from the website. Maybe we will find out one day. Still, Bleepa looks really good, I like it and can quite clearly see the urgent need for such product to be rolled out to assist in the massive mountain of backlog self inflicted wound at the NHS. An institution we were meant to protect and save is in danger of collapsing within. Remains to be seen if Tom can pull off the deal of the century but I remain optimistic that if we continue to see adoption it could lead to a snowball effect. If covid slowed progress then it may have left an ideal situation for Bleepa to now thrive. 1p share price is reflective of this situation and at this level there should be some Fomo too I hope.
petekand
21/6/2021
17:13
Cash burn in 12months £3.5million? Sarted with0.7mill raised 5mill, balance £2.2mill, LR2 will correct if wrong.
hulk2004
21/6/2021
17:07
You cannot go on £120k banked in June and extrapolate for year, company would have indicated that this rate of income would continue if so. Results very poor and cash burn high, placing will be before year is out but agree IQAI revenues stated are poor as well, so a lot to do there to.
hulk2004
21/6/2021
15:30
Trevor, FDBK banked £120k in the first 8 days of the current financial year. "The Company has already invoiced £0.12 million of revenue to be recognised during the current financial year in accordance with the Company's accounting policies and the Directors expect revenues to grow as sales of Bleepa increase during the rest of the financial year." If they do similar throughout year then 365 days / 8 x £120k = £5.475 mil for the year. Let's be cautious and say they only get £120k every 20 days then 365 / 20 x £120k = £2.19 mil for the year. Add on expected TexRAD income and the yearly revenue will be around £2.47 mil. Almost ten times the revenue currently achieved by IQAI. That will cover expenses I believe. Now IQAI had £255,314 revenue for last financial year and admin expenses of £933,462. Group loss of £717,534 after tax. Where are your sales / contracts 'meat'? LA County hospital isn't going to cut it, is it? Especially when you don't even indicate what kind of a bankable sum you will get for this, your one and only contract this year.
lr2
21/6/2021
14:19
8050 New 8051 Old but worth listening to again. Interesting listening to comments about AI. Didn't they very recently link to an AI article? Thanks again! Potential inclusion in the HealthTech 50 but no contract announced. Notice they still had Feedback headquarters as Cambridge not London as it is now. Https://businesscloud.co.uk/healthtech-50-vote/
ged5
21/6/2021
13:43
Almost new. 3 days old but I haven't seen it mentioned here. Tom starts talking at 02:15. Lasts about 10 mins. Https://www.voxmarkets.co.uk/articles/feedback-plc-chris-bailey-on-3-big-caps-john-meyer-on-3-small-resource-stocks-f9fb958/
lr2
21/6/2021
13:37
I think this is new. Https://bleepa.com/clinical-information-data-quality-and-auditing
lr2
18/6/2021
23:28
Nice find LR2. Just hope the word gets around the hospitals.
digger2779
18/6/2021
22:30
Https://twitter.com/FBKmed/status/1405903466493616129 Https://o8k.7f4.myftpupload.com/wp-content/uploads/2021/06/Bleepa_A4-landscape-leave-behind_v2-1-1.pdf
lr2
18/6/2021
12:08
I didn’t need a smartphone untill I got one!
ducatiman
18/6/2021
11:30
I admit to having spoken to only one radiologist about Bleepa. She was extremely interested in Bleepa and considered it to be of value. The last time I spoke to her she was going to find out more. I've no idea if she has or not but her reaction indicated that what was in place wasn't sufficient. From what I read from Aunt Minnie and other radiology reports there is a need for improvements which might help rectify the big shortage of radiologists.
ged5
18/6/2021
10:34
Interesting Ged5 but all the potential users are already going about their day-jobs without a deficit on communications (I am in frequent contact with radiology departments of hospitals). From my research, the presumption of need originates only from Feedback, i.e not real. Real need would surely be reflected by commercial interest after all this time? Call a couple of radiology departments in hospitals and find our for yourself
ydderf
18/6/2021
09:49
"Clinical users at hospitals with a Bleepa contract will be able to download the app on both Apple App Store and Google Play. The CE marked medical device is the only regulated platform on the NHSX Clinical Communications Framework that allows users to share images at a standard approved for clinical use." Https://www.digitalhealth.net/2021/06/industry-news-in-brief-41/
ged5
17/6/2021
13:31
Yump's first law states that when not many people are interested in a share and there is a frustrating lack of progress, leading to people looking for hints of progress, then its probably the best time to buy. Yump's second law states that yump's first law only applies, when you've done your analysis of features and benefits of the product and found out that it has no significant direct competitors. But who cares anyway about anyone's apparent "cleverness" on here.
yump
17/6/2021
12:33
If Occam's razor is applied, the most likely explanation is that it was considered market sensitive and taken down, but in this case there would have been an RNS by now, or it was wrong and therefore misleading and taken down......either way, the share price is eloquent ydderF's law states that when bulletin boards are focused on minutiae like how many shares were traded at what price (often a few hundred quids worth in this share) and what obscure mention it got on some obscure third party website, it is not a healthy development......
ydderf
17/6/2021
12:01
Has anyone contacted the company for an explanation?
ducatiman
Chat Pages: 461  460  459  458  457  456  455  454  453  452  451  450  Older
ADVFN Advertorial
Your Recent History
LSE
FDBK
Feedback
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210625 04:32:51